Biophytis S.A. (EPA:ALBPS)
France · Delayed Price · Currency is EUR 0.0631
-0.0038 (-5.68%)
At close: Jan 30, 2026
Biophytis Company Description
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases.
The company’s lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD).
It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD.
The company was incorporated in 2006 and is headquartered in Paris, France.
Biophytis S.A.
| Country | France |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Stanislas Veillet |
Contact Details
Address: 14 avenue de l'Opéra Paris, 75001 France | |
| Phone | 33 1 44 27 23 00 |
| Website | biophytis.com |
Stock Details
| Ticker Symbol | ALBPS |
| Exchange | Euronext Paris |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0012816825 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Stanislas Veillet Ph.D. | Chairman of the Board and Chief Executive Officer |
| Waly Dioh Ph.D. | Chief Clinical Operating Officer |
| Dr. Pierre J. Dilda Ph.D. | Chief Scientific Officer |
| Dr. Rene Lafont | Scientific Advisor and Member of Scientific Advisory Board |
| Edouard Bieth | Chief Strategy Officer |
| Chiara Baccelli | Chief Pharmaceutical Operations Officer and Quality Assurance Director |
| . Teylan | Financial Controller |